{"created":"2023-06-20T15:55:37.632066+00:00","id":12214,"links":{},"metadata":{"_buckets":{"deposit":"b0ffe938-a6c4-47ff-b38c-f2add6cc1c97"},"_deposit":{"created_by":39,"id":"12214","owners":[39],"pid":{"revision_id":0,"type":"depid","value":"12214"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00012214","sets":["98:61:420"]},"author_link":["44350","27650","908","27646","26914","7289","34075","12080","910","34079","27651","44361"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-03-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"45","bibliographicPageStart":"43","bibliographicVolumeNumber":"40","bibliographic_titles":[{"bibliographic_title":"高山赤十字病院紀要"},{"bibliographic_title":"Japanese Red Cross Takayama Hospital","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"A lot of studies of O6-methyguanine DNA methyltransferase (MGMT) protein expression have\nbeen reported in glioma. However, there are few reports assessed the protein expression in other\nbrain tumors except glioma.\nMETHODS: Five brain tumors except glioma (two primary central nervous system lymphomas;\nPCNSLs, one germinoma, one hemangioblastoma, and one Rathke’s cleft cyst) were immunostained\nusing a commercial anti-MGMT antibody (Chemicon international:MAB16200;clone MT3.1). Three\nglioblastomas were also immunostained with the same antibody. We assessed MGMT protein\nexpression semiquantitatively (low expression was defined as 20～50% immunostained tumor cells,\nand high expression was defined as ＞50% immunostained tumor cells ).\nRESULTS: Two PCNSLs were assessed as high expression. Germinoma was also assessed as high\nexpression. In contrast, Hemangioblastoma was assessed as low expression and Rathke’s cleft\ncyst was no expression.\nCONCLUSIONS: By using immunohistochemical assessment of MGMT protein expression, it might\nhelp us to understand the features in brain tumors except glioma.","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"高山赤十字病院"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0387-7027","subitem_source_identifier_type":"ISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"西脇, 崇裕貴"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"竹中, 勝信"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"加藤, 雅康"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"野中, 裕康"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"趙, 振新"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"岡本, 清尚"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-08-14"}],"displaytype":"simple","filename":"10西脇崇裕貴.pdf","filesize":[{"value":"41.2 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"takayama40_010","url":"https://redcross.repo.nii.ac.jp/record/12214/files/10西脇崇裕貴.pdf"},"version_id":"0d6e3591-ca46-46dc-b47d-43fd309e4f00"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"MGMT","subitem_subject_scheme":"Other"},{"subitem_subject":"lymphoma","subitem_subject_scheme":"Other"},{"subitem_subject":"immunostaining","subitem_subject_scheme":"Other"},{"subitem_subject":"MGMT","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"lymphoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immunostaining","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"悪性神経膠芽腫（グリオーマ）以外の脳腫瘍における O6-methylguanine-DNA methyltransferase （MGMT）抗体の染色性の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"悪性神経膠芽腫（グリオーマ）以外の脳腫瘍における O6-methylguanine-DNA methyltransferase （MGMT）抗体の染色性の検討"},{"subitem_title":"Immunohistochemical study of O6-methyguanine DNA methyltransferase in brain tumors except glioma","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"39","path":["420"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-08-14"},"publish_date":"2017-08-14","publish_status":"0","recid":"12214","relation_version_is_last":true,"title":["悪性神経膠芽腫（グリオーマ）以外の脳腫瘍における O6-methylguanine-DNA methyltransferase （MGMT）抗体の染色性の検討"],"weko_creator_id":"39","weko_shared_id":-1},"updated":"2023-06-20T19:05:06.655283+00:00"}